Second autologous hematopoietic stem cell transplantation in multiple sclerosis: a single center prospective experience.

Abstract

Immunosuppressive therapy is useful in persons with multiple sclerosis (MS), and autologous hematopoietic stem cell transplantation (aHSCT) is the most effective immunosuppressive treatment in this setting. Information on the usefulness of a second aHSCT in patients with MS is scarce. In a group of 1225 individuals with MS prospectively managed with aHSCT, we analyzed the salient features of 4 patients who received two consecutive transplants. After a moderate initial response to the first aHSCT, the patients were transplanted again after deterioration of their neurological status; the second transplant was well tolerated and, in all instances, was completed on an outpatient basis, and with no associated undesired toxicity. The autograft protocol is registered in ClinicalTrials.gov, identifier NCT02674217. After the second graft, the expanded disability status scale score stabilized in two patients; in one, the post-transplant period is too short to assess the response, and in another, the development of associated Parkinson´s disease precluded the assessment of the outcome. In conclusion, a second aHSCT in persons with MS is feasible, safe, and may lead to a positive response in some cases.